Close

Nektar Therapeutics (NKTR) Presentation Offers Encouraging Ph1 Data - BTIG

June 14, 2019 6:13 AM EDT Send to a Friend
BTIG analyst Robert Hazlett reiterated a Buy rating and $101.00 price target on Nektar Therapeutics (NASDAQ: NKTR) after the company ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login